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Introduction
Bacteriophage vectors have potential as vaccine delivery
and gene transfer vectors because of their genetic tracta-
bility, inexpensive production and suitability for large-
scale production (Chen and Lim 1996), as well as their
physical stability and compatibility with simple storage
and formulation methods such as desiccation (Jepson
and March 2004). In addition, phages have been experi-
mentally administered to animals and safely used in
humans for applications that include the treatment of
bacterial infections (reviewed in Barrow and Soothill
1997; Stone 2002), and more recently, recombinant
phage coat proteins, which form virus-like particles,
have also been used for immunization (Maurer et al.
2005).
Larocca et al. (1998,1999) have shown that ﬁlamentous
phage vectors displaying host-derived ligands on their
surface can undergo receptor-mediated endocytosis,
resulting in the expression of phage-encoded genes in
mammalian cells. Similarly, lambda phage can be targeted
to mammalian cells by surface display of appropriate pro-
teins or peptides (Dunn 1996).
March and colleagues have shown that immunization
of mice and rabbits with unmodiﬁed lambda phage parti-
cles encoding the hepatitis B surface antigen (HBsAg) or
antigens derived from Mycoplasma mycoides under control
of the cytomegalovirus (CMV) promoter results in a
strong antigen-speciﬁc humoural immune response (Clark
and March 2004; March et al. 2004,2006; ). These results
indicate that even unmodiﬁed, nontargeted lambda phage
particles can mediate in vivo gene delivery, possibly
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Abstract
Aims: Bacteriophage vectors have potential as gene transfer and vaccine deliv-
ery vectors because of their low cost, safety and physical stability. However, lit-
tle is known concerning phage-mediated gene transfer in mammalian hosts.
We therefore performed experiments to examine phage-mediated gene transfer
in vivo.
Methods and Results: Mice were inoculated with recombinant lambda phage
containing a mammalian expression cassette encoding ﬁreﬂy luciferase (luc).
Efﬁcient, dose-dependent in vivo luc expression was detected, which peaked
within 24 h of delivery and declined to undetectable levels within a week. Dis-
play of an integrin-binding peptide increased cellular internalization of phage
in vitro and enhanced phage-mediated gene transfer in vivo. Finally, in vivo
depletion of phagocytic cells using clodronate liposomes had only a minor
effect on the efﬁciency of phage-mediated gene transfer.
Conclusions: Unmodiﬁed lambda phage particles are capable of transducing
mammalian cells in vivo, and may be taken up – at least in part – by nonphag-
ocytic mechanisms. Surface modiﬁcations that enhance phage uptake result in
more efﬁcient in vivo gene transfer.
Signiﬁcance and Impact of the Study: These experiments shed light on the
mechanisms involved in phage-mediated gene transfer in vivo, and suggest new
approaches that may enhance the efﬁciency of this process.
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(APCs) (Clark and March 2004).
In this article, we present a number of in vivo ﬁndings
pertinent to the future development of lambda as both a
vaccine delivery vector and a gene transfer vector. In the
experiments presented, we used a trans-complementation
system to produce lambda phage particles bearing differ-
ent versions of the gpD coat protein (Zanghi et al.
2005). These particles contained a modiﬁed lambda
phage genome that incorporates a CMV promoter-driven
mammalian luciferase (luc) reporter gene cassette
(Eguchi et al. 2001; Zanghi et al. 2005). We then used
these phage particles to characterize phage-mediated gene
transfer in vivo, using a real-time imaging system. These
studies provide proof-of-concept support for the notion
that directed targeting of lambda phage vectors, through
surface protein modiﬁcation, may result in more efﬁcient
gene transfer in vivo. This study also suggests that phage
vectors may be taken up, at least in part, via nonphago-
cytic mechanisms, possibly including macropinocytosis.
These ﬁndings offer important insight into the basis for
phage-mediated gene transfer and suggest possible modi-
ﬁcations for improving phage-based vaccine delivery
systems.
Materials and methods
LambdaD1180 (luc) lysogens
LambdaD1180 (no luc) and lambdaD1180 (luc) lysogens
(Dam15 del EcoRI-SacI cIts857 nin5 Sam100) were provi-
ded by Dr Mahito Nakanishi (Eguchi et al. 2001).
LambdaD1180 (luc) lysogens contain the ﬁreﬂy luc gene,
under the transcriptional control of the CMV immediate
early promoter; lambdaD1180 (no luc) lysogens contain
no insert.
pTrc-gpD expression plasmids
The pTrc-gpD, pTrc-CDF-gpD and pTrc-gpD-3JCLI4
expression plasmids have been described (Zanghi et al.
2005). The pTrc-gpD-3JCLI4 plasmid encodes gpD, fused
to a high-afﬁnity avb3 binding protein (3JCLI4) (Richards
et al. 2003; Zanghi et al. 2005).
Lambda phage preparation
Lysogens of Escherichia coli TOP10 cells (Invitrogen, Carls-
bad, CA, USA) containing lambdaD1180 (no luc) or lamb-
daD1180 (luc) were transformed with the pTrc-gpD
plasmid containing wild-type gpD. Additionally, lamb-
daD1180 (luc) lysogens were cotransformed with the pTrc-
gpD-3JCLI4 and gpD-CDF-gpD plasmids (Zanghi et al.
2005). Lysogens were induced as described, and phages
were puriﬁed by CsCl density gradient centrifugation, prior
to titrating on LE392 E. coli cells and immunoblot analysis
(to verify the presence of the expected recombinant forms
of gpD) (Zanghi et al. 2005).
LambdaD1180 (luc) lysogens were also prepared via a
lytic method to produce phage complemented with
phage-encoded gpD. In this case, phages prepared lytically
were grown in E. coli host cells that contained an amber
suppressor tRNA and thus could produce a functional
gpD coat protein from the amber-mutated gpD gene con-
tained in the phage genome. To do this, LE392 E. coli
cells (e14-(McrA-) hsdR514 supE44 supF58 lacY1 or
DD(lacIZY)6 galK2 galT22 metB1 trpR55) grown in
NZCYM plus 0Æ2% maltose were infected with gpD (luc)
phage and grown at 37 C until lysis was observed. Upon
lysis, chloroform (Sigma, St Louis, MO, USA) was added
to lyse the remaining intact host cells and DNase I
(Worthington Biochemical Corp., Freehold, NJ, USA) was
added to a ﬁnal concentration of 1 lgm l
)1 to remove
contaminating nucleic acids. NaCl was added to a ﬁnal
concentration of 1 mol l
)1 and lysates were cleared by
centrifugation. Phage was precipitated by the addition of
polyethylene glycol-8000 (PEG; Sigma-Aldrich) to a ﬁnal
concentration of 10% (w/v). Precipitated phage particles
were pelleted by centrifugation, resuspended in suspen-
sion media (SM; 100 mmol l
)1 NaCl, 10 mmol l
)1
MgSO4Æ7H2O, 50 mmol l
)1 Tris–HCl (pH 7Æ5), 0Æ1% gel-
atin), extracted with chloroform and puriﬁed by CsCl
density gradient ultracentrifugation. Puriﬁed phages were
dialysed against 10 mmol l
)1 NaCl, 50 mmol l
)1 Tris–
HCl (pH 8Æ0), 10 mmol l
)1 MgCl2, prior to titrating on
LE392 E. coli cells.
Mice
BALB/c mice were obtained from Taconic Laboratories
(Hudson, NY, USA) and maintained according to Univer-
sity of Rochester and NIH guidelines. Mice were injected
intradermally (ID), via the tail base, intramuscularly
(IM), in the thigh, or via the intraperitoneal (IP) route,
using a 28G, 0Æ5 inches, 0Æ5 ml insulin syringe (BD Bio-
sciences, San Jose, CA, USA).
In vivo imaging of luciferase expression
Mice were injected with CsCl-puriﬁed lambda phage, puri-
ﬁed lambda luc DNA, a luc reporter plasmid (gWiz; Aldev-
ron, Fargo, ND, USA), in 50 or 100 ll total volume. Luc
expression was detected using a Xenogen IVIS system
(Hopkinton, MA, USA) to image in vivo bioluminescence
in real time (Fan et al. 2005); luc expression was conﬁned
to the local site of injection in all cases.
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Mice were killed following imaging and 6 mm tail base
tissue samples (from the local site of phage injection)
were collected using a tissue punch. Tissue samples were
added to 1· passive lysis buffer (Promega, Madison, WI,
USA) and cryopreserved at )80 C. Prior to homogenate
preparation, tissues were thawed, ﬂash frozen in liquid
nitrogen, pulverized, resuspended in 1· passive lysis
buffer and homogenized (Ultrathurrax, Ika-Werke, Ger-
many). Protein concentrations were determined by Brad-
ford assay (Bio-Rad, Hercules, CA, USA). Luc activity
was determined as described (Fan et al. 2005). Prior to
the analysis, homogenates were thawed and 25 ll of the
lysate (0Æ5 lg ll
)1) was combined with 25 ll of ﬁreﬂy luc
substrate (Promega). Light emission was measured in a
white 96-well plate using the SpectraCount version 3.0
luminometer (Packard; Perkin Elmer, Boston, MA, USA).
DNase I treatment
DNase I (10 U; New England Biolabs, Ipswich, MA, USA)
or DNase I buffer (10 mmol l
)1 Tris–HCl, 2 mmol l
)1
CaCl2, 100 lg/ml BSA, 50% glycerol) was added to
1 · 10
11 PFU of gpD (luc) bacteriophage or 1 · 10
11 PFU
of gpD (no luc) physically mixed with 5 lg of lambda luc
DNA in a total volume of 50 ll of SM. After incubation at
37 C for 30 min, DNase I or DNase I buffer-treated
(mock) phage or phage plus DNA was injected into mice
and luc expression was imaged 24 h later.
Pre-immunization with bacteriophage lambda
Mice were pre-immunized via IM injection with either
1 · 10
11 PFU of gpD (no luc) in 50 ll total volume, or
50 ll of SM alone. Immediately prior to immunization,
serum was collected. Two weeks following immunization,
serum was again collected and mice were then injected ID
with 1 · 10
11 PFU of gpD (luc) phage in 50 ll total
volume. Twenty-four hours later, luc expression was
imaged.
ELISA detection of bacteriophage lambda antibodies
from sera
Sera collected were tested by ELISA for the presence of
antibodies directed against bacteriophage lambda. Micro-
titre plates were coated overnight at 4 C with
1 · 10
9 PFU of wild-type bacteriophage lambda (strain
W60; ATCC) diluted in 1· phosphate-buffered saline
(PBS). After blocking with 3% BSA in 1· PBS, sera were
added to wells in serial fourfold dilutions in 3% BSA in
1· PBS. Wells were washed and horseradish-peroxidase-
conjugated anti-mouse IgG (Fc speciﬁc; Sigma) was
added at a dilution of 1:70 000 in 3% BSA in 1· PBS.
Wells were developed with Sure Blue substrate (KPL,
Gaithersburg, MD, USA) and read at an absorbance of
450 nm. It is noted that this IgG-speciﬁc ELISA may
underestimate antibody titres to a single phage vaccin-
ation, as it will fail to detect other antibody classes (such
as IgM).
In vitro internalization assay
The K562-avb3 cells (expressing avb3 integrin on their
surface) were provided by Dr Scott Blystone (SUNY
Upstate Medical University, Syracuse, NY, USA) and were
incubated in 96-well plates with various concentrations of
puriﬁed 3JCLI4 protein (provided by Casey Maguire) for
15 min at 4 C prior to the addition of phage. Either gpD
(luc) or 3JCLI4 (luc) phage was added to cells at a multi-
plicity of infection (MOI) of 1 · 10
5, centrifuged for
15 min and incubated at 37 C for an additional 1 h and
45 min. Following incubation, cells were washed with an
ice-cold acid wash (0Æ3 mol l
)1 acetic acid, 0Æ5 mol l
)1
NaCl, pH 2Æ5) and manually lysed by passing through a
28G, 0Æ5 inches, 0Æ5 ml insulin syringe. This results in
>99% lysis of cells, as measured by trypan blue dye exclu-
sion. Internalized phages in the cell lysates were then
quantiﬁed by titration on LE392 E. coli cells. It is noted
that this assay almost certainly underestimates phage
internalization as it counts only those phages that remain
intact and infectious for E. coli (and does not count
phage particles that may be fully or partially degraded).
In vitro analysis of luc expression
The K562-avb3 cells and control K562 cells were seeded
in 96-well plates. Either gpD (luc) or 3JCLI4 (luc) phage
was then added to cells at MOI of 1 · 10
5, and the plates
were subjected to centrifugation at 900 g for 15 min, in
order to enhance the efﬁciency of phage binding to the
target cells (O’Doherty et al. 2000; Scanlan et al. 2005;
Harui et al. 2006a). After this, the cultures were returned
to a 37 C incubator for an additional 1 h and 45 min.
Following incubation, phage-containing media were
removed, cells were washed once and incubated in com-
plete media to allow for luc expression. Forty-eight hours
later, 1· passive lysis buffer was added and cells were sub-
jected to two freeze/thaw cycles to ensure cell lysis. Pro-
tein concentrations from cell lysates were normalized
using a Bradford assay. Luc activity was determined as
described (Fan et al. 2005). Prior to analysis, 20 ll of the
lysate was combined with 100 ll of ﬁreﬂy luc substrate.
Light emission was measured in a white 96-well plate
using the SpectraCount version 3.0 luminometer.
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The phages were suspended in 10% normal mouse serum
(diluted in SM), at a ﬁnal concentration of approx.
2 · 10
10 PFU ml
)1 and were then incubated for 30 min
at 37 C prior to titrating on LE392 E. coli cells. Similar
experiments were conducted by incubating phage with
various concentrations of EDTA and SDS for 30 min at
room temperature prior to titrating on LE392 E. coli cells.
Macrophage depletion via clodronate liposomes
Clodronate was purchased from Sigma and clodronate
liposomes were generated using methods developed by
van Rooijen et al. (van Rooijen and van Nieuwmegen
1984; van Rooijen et al. 1989; van Rooijen and van Kest-
eren-Hendrikx 2002). BALB/c mice were injected with
clodronate liposomes via a combined ID (100 ll) and IP
(200 ll) route. Forty-eight hours following clodronate
liposome injection, mice were injected ID with phage or
DNA, and IVIS imaging was performed 24 h thereafter.
Mice were then killed and splenocytes were subjected to
ﬂow cytometric analysis using monoclonal antibodies spe-
ciﬁc for the myeloid marker F4/80 (antibody provided by
Dr Edith Lord).
Results
In vivo luciferase expression in BALB/c mice
To examine the mechanism(s) involved in in vivo gene
expression from bacteriophage lambda vectors, a phage
containing a ﬁreﬂy luc expression cassette was used to per-
form real-time analysis of luc expression in vivo. We ﬁrst
performed a dose–response analysis, in which mice were
injected ID, via the tail base, with 1 · 10
10,5 · 10
10,
1 · 10
11,o r5 · 10
11 PFU of gpD (luc) phage or
1 · 10
11 PFU of gpD (no luc) phage, in 50 ll total volume.
Twenty-four hours later, luc expression was measured.
In vivo luc gene expression was found to correlate with
phage dose (Fig. 1) and to be localized to the local site of
vector delivery at the tail base (Supplementary data,
Fig. 1S). On the basis of these results, a dose of
1 · 10
11 PFU was chosen for use in follow-up experiments.
Time course analysis of phage-mediated gene expression
The time course of phage-mediated gene expression was
analysed, following ID delivery of either gpD (luc) particles
or puriﬁed genomic lambda luc DNA alone (Fig. 2). In this
experiment, 5 lg of puriﬁed genomic lambda luc DNA was
used, as this corresponds to the expected amount of ge-
nomic lambda DNA contained in 1 · 10
11 PFU of lambda
phage particles. Luc expression peaked at the 24 h time
point in both cases, and declined to undetectable levels
within 7 days of injection of phage particles. Expression
from the puriﬁed lambda luc DNA alone showed a trend
towards a more prolonged duration, but this result did not
achieve statistical signiﬁcance.
Treatment of puriﬁed phage with DNase I does not
affect in vivo luciferase expression
Jepson and March (2004) have demonstrated that lambda
phage particles represent a highly stable DNA transfer sys-
tem. This ﬁnding suggests that phage-encapsidated DNA
is protected from environmental damage, but can be
released within mammalian cells, following uptake of
phage particles. This prediction was experimentally tested,
by treating CsCl-gradient puriﬁed lambda phage particles
encoding a luc reporter gene with DNase I and then
administering the treated phage particles to mice. As
shown in Fig. 3, DNase I treatment of gpD (luc) phage
had no effect on in vivo luc expression. The DNase I
treatment was sufﬁcient to degrade 5 lg of exogenous
lambda luc DNA in the presence of 1 · 10
11 PFU of
phage and eliminate luc signal in this group.
In vivo luc expression in BALB/c mice injected with gpD
(luc) phage is increased when mice are pre-immunized
with bacteriophage lambda.
The human intestinal tract is colonized by commensal
microbial ﬂora that includes E. coli. This, combined with
the isolation of bacteriophages from raw sewage and fae-
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Figure 1 In vivo luciferase (luc) expression in BALB/c mice is dose
dependent. Mice (three per group) were injected ID at the tail base
with 1 · 10
10,5· 10
10,1· 10
11 or 5 · 10
11 PFU of gpD (luc) phage
or 1 · 10
11 PFU of gpD (no luc) phage. Twenty-four hours later, luc
expression was imaged at the tail base site of injection. The graph is
representative of the average photon ﬂux (photons sec
)1 cm
)2 sr
)1)
and SD for each group.
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some humans may harbour enteric coliphages. Consistent
with this, coliphage neutralizing activity has been detected
in normal human serum (Cowan 1962).
While the seroprevalence of lambda phage-speciﬁc anti-
bodies within human populations is not known, such
antibodies might represent a barrier to the use of phage
lambda in humans. An experiment was therefore conduc-
ted to determine the impact of pre-existing immunity to
bacteriophage lambda on the efﬁciency of lambda-vec-
tored reporter gene expression in vivo. To do this, mice
were pre-immunized with wild-type bacteriophage
lambda. Two weeks later, mice were injected ID with
1 · 10
11 PFU of gpD (luc) phage. A statistically signiﬁ-
cant increase in luc expression was detected in the pre-
immunized mice (which had high titres of phage-speciﬁc
antibodies), when compared to control mice (Fig. 4).
Thus, pre-existing immunity to bacteriophage lambda
failed to neutralize locally delivered phage particles, and
in fact, had an enhancing effect on vector-mediated gene
transfer.
3JCLI4 (luc) phage targets avb3 integrin in vitro and
increases in vivo luciferase expression
We have previously described the construction of luc-
encoding phage vectors in which the major phage coat
protein (gpD) is fused to an avb3 integrin-binding pep-
tide (3JCLI4) (Richards et al. 2003). This peptide binds
with high afﬁnity and speciﬁcity to avb3, but not to other
integrins (Richards et al. 2003).
We sought to determine the ability of this targeted
phage to speciﬁcally internalize into mammalian cells
expressing avb3 in vitro. We elected to target this integrin
for two major reasons. First, this receptor is known to
play a role in the binding and/or internalization of a
number of mammalian viruses – including adenoviruses
(Wickham et al. 1993; Mathias et al. 1994; Huang et al.
1995) and some hantaviruses (Gavrilovskaya et al. 1998;
Song et al. 2005). Secondly, the receptor has been success-
fully used to enhance the targeting of modiﬁed virus vec-
tors to dendritic cells (Asada-Mikami et al. 2001; Okada
et al. 2001; Harui et al. 2006b; Maguire et al. 2006),
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Figure 2 In vivo luciferase (luc) expression in BALB/c mice injected with wild-type luc-encoding phage persists over a time frame very similar to
that of mice injected with puriﬁed lambda luc DNA. Mice (eight per group) were injected ID at the tail base with either 1 · 10
11 PFU of wild-type
gpD (luc) phage (panels a, c) or 5 lg of puriﬁed lambda luc DNA (panels b, d); note that 5 lg DNA corresponds to the expected amount of
genomic lambda DNA contained in 1 · 10
11 PFU of lambda phage. Luc expression was measured at the tail base site of injection, 1, 3, 5, 7, and
10 days following injection. Results shown in panels a and b represent mean luc expression values ± SDs. In vivo luc expression in mice injected
with gpD (luc) is similar to expression levels obtained from mice injected with 5 lg puriﬁed lambda luc DNA. Panels c and d represent an analysis
of luc expression in each of the individual eight animals from each experimental group that is represented in the summary graphs (panels a and
b). The dashed horizontal line drawn across each of the panels denotes the cut-off of the assay (1 · 10
5 photons sec
)1 cm
)2 sr
)1).
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1997).
Wild-type gpD (luc) or 3JCLI4 (luc) phage was incuba-
ted with K562-avb3 cells in the presence or absence of var-
ious concentrations of competing, soluble 3JCLI4 protein.
Following an acid wash to remove extracellular phages, cell
lysates were prepared, and internalized phage were titrated
on LE392 E. coli cells. 3JCLI4 (luc) showed increased inter-
nalization vs gpD (luc) phage. 3JCLI4 (luc) internalization
was reduced by the addition of soluble, competitor 3JCLI4
protein, in a dose-dependent fashion, indicating that inter-
nalization occurred in a receptor-speciﬁc manner (Fig. 5a).
This result was conﬁrmed by an analysis of phage-
mediated gene transfer in parental K562 cells and K562-
avb3 cells, following spinoculation with wild-type gpD
(luc) or 3JCLI4 (luc) (O’Doherty et al. 2000; Scanlan
et al. 2005; Harui et al. 2006a). This experiment revealed
that the 3JCLI4 (luc) phage elicited a higher level of luc
expression in K562-avb3 cells when compared with paren-
tal K562 cells, whereas no such enhancement was detected
when cells were incubated with the wild-type gpD (luc)
phage (Fig. 5b). Collectively, these in vitro data show that
3JCLI4 (luc) can be targeted to cells expressing avb3.
We next examined the effect of vector targeting on luc
gene expression in vivo. BALB/c mice were injected ID
with 1 · 10
11 PFU of either wild-type gpD (luc) phage or
3JCLI4-targeted (luc) phage. A control group of animals
received gpD (no luc) phage lacking the luc insert. Luc
expression was then examined by two independent assays
at 1 and 3 days following phage inoculation. First, luc
activity was measured in tissue homogenates that were
prepared from the local injection site at which the phage
particles were injected. Luc activity in these tissue homo-
genates was normalized in terms of protein content and
the results are shown in Fig. 5(c). Higher levels of luc
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Figure 3 Luciferase (luc)-encoding phage is resistant to DNase I treat-
ment. Mice (eight per group) were injected ID at the tail base with
1 · 10
11 PFU of gpD (luc) phage that were either treated with 10 U
of DNase I for 30 min at 37 C prior to injection, or not exposed to
DNase I. As a control, mice (four per group) were injected with
1 · 10
11 PFU of matching phage that lacked the luc expression cas-
sette (no luc), which were physically mixed with 5 lg of lambda luc
DNA and then either treated with 10 U of DNase I for 30 min at
37 C prior to injection, or not exposed to DNase I. Twenty-four hours
later, luc expression was measured at the tail base site of injection.
DNase I treatment had no detectable effect on luc expression levels in
mice that were injected with gpD (luc) phage (P >0 Æ05, Student’s
two-tailed t-test). However, the amount of DNase I added was sufﬁ-
cient to degrade 5 lg of exogenous DNA (compare luc expression lev-
els in the two no luc groups).
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Figure 4 In vivo luciferase (luc) expression in BALB/c mice injected
with gpD (luc) phage is increased when mice are pre-immunized with
bacteriophage lambda. Mice were immunized IM with either
1 · 10
11 PFU of gpD (no luc) bacteriophage lambda (lambda) in 50 ll
of suspension media or 50 ll of suspension media alone (SM only).
Two weeks postimmunization, all mice were injected ID at the tail
base with 1 · 10
11 PFU of gpD (luc) phage, and luc expression was
then measured 24 h later at the tail base site of injection. (a) Data
shown represent mean luc expression values ± SDs; the data shown
were combined from two separate experiments that used a total of
seven mice. There was a statistically signiﬁcant difference in in vivo
luc gene expression between mice that were pre-immunized with bac-
teriophage lambda vs mice that were pre-immunized with suspension
media alone (P <0 Æ05, Student’s two-tailed t-test). (b) Sera were col-
lected from mice at 14 days following the initial phage immunization
and analysed for lambda-speciﬁc IgG antibodies by ELISA. Antibodies
speciﬁc for bacteriophage lambda were detected in mice pre-immun-
ized with bacteriophage lambda, but not in control mice.
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Figure 5 3JCLI4 (luc) phage targets avb3 in vitro and increases in vivo luc expression. (a) K562-avb3 cells were incubated with gpD (luc) (j)o r
3JCLI4 (luc) ( ) phage (containing a modiﬁed gpD protein bearing the 3JCLI4 integrin-binding peptide) at an MOI of 10
5, in the presence or
absence of increasing concentrations of soluble 3JCLI4 protein. Two hours later, cells were washed and lysates were prepared in order to quantify
internalized phage, which were then titrated on LE392 Escherichia coli cells. Data shown represent mean phage titres ± SDs (calculated from three
independently analysed wells of a cell culture dish, each of which was titrated in triplicate). There was a statistically signiﬁcant increase in phage
internalization between the 3JCLI4 (luc) phage particles and the gpD (luc) phage particles (*P <0 Æ05, two-way anova, Tukey’s post-test). In addi-
tion, internalization of the 3JCLI4 (luc) phage was reduced, by the addition of soluble 3JCLI4 protein, in a dose-dependent fashion (this reduction
was statistically signiﬁcant at all concentrations of soluble 3JCLI4 that were added; P <0 Æ001 in all cases, two-way anova, Tukey’s post-test). (b)
gpD (luc) (j) or 3JCLI4 (luc) ( ) phage was added to K562-avb3 or wild-type K562 cells in 96-well plates, at an MOI of 10
5. The plates were sub-
jected to centrifugation at 900 g for 15 min, in order to enhance the efﬁciency of phage binding to the target cells (O’Doherty et al. 2000; Scan-
lan et al. 2005; Harui et al. 2006a). After this, the cultures were returned to a 37 C incubator for 1 h and 45 min, and the cells were then
washed to remove unbound phage. The cultures were again returned to a 37 C incubator, and 48 h later, cell lysates were prepared. After nor-
malization of the protein content of the cell lysates, luc expression was measured. Data shown represent mean luc expression values ± SDs (calcu-
lated from three independent experiments, each of which analysed triplicate wells of a cell culture dish). There was a statistically signiﬁcant
increase in luc expression between the 3JCLI4 (luc) phage particles and the gpD (luc) phage particles, when tested in K562-avb3 cells but not
when tested in wild-type K562 cells (*P <0 Æ05, two-way anova, Tukey’s post-test). Thus, 3JCLI4 (luc) can be targeted to cells expressing avb3. (c,
d) To examine the ability of 3JCLI4 (luc) to increase in vivo gene delivery, mice (eight per group) were injected ID at the tail base with
1 · 10
11 PFU of either gpD (luc) phage or 3JCLI4 (luc) phage (containing a modiﬁed gpD protein bearing the 3JCLI4 integrin-binding peptide). As
a negative control, four mice were injected with 1 · 10
11 PFU of gpD (no luc). (c) Mice were killed at either 1 or 3 days following phage injection,
and the tail base site of injection was excised using a tissue punch. The tissue sample was then homogenized in luc sample buffer, and luc activity
was measured using a chemiluminescent assay; results are expressed as relative light units (RLU) per lg of tissue extract. Data shown represent
mean luc expression values ± SDs (four mice per group). There was a statistically signiﬁcant difference in in vivo luc gene expression between mice
that received 3JCLI4 (luc) phage particles vs animals that received the gpD (luc) phage particles at the 3-day time point (P <0 Æ05, Student’s two-
tailed t-test). The data for the 1-day time point did not achieve statistical signiﬁcance. In this experiment, the control group (which received ‘no
luc’ phage) was analysed at 1 day following phage delivery (only). The analysis of control animals was not repeated at the 72-h time point (N.D.),
because it was felt that a single time point was sufﬁcient to establish the background in the luc assay (h,2 4h ;j, 72 h). (d) Luc expression was
analysed at the tail base site of injection in live animals at the day 1 and 3 time points, using the Xenogen IVIS system. Data shown represent
mean luc expression values ± SDs (eight mice per group at day 1 and four mice per group at day 3). In vivo luc gene expression was found to be
greater in animals injected with 3JCLI4 (luc), although this increase did not achieve statistical signiﬁcance (P >0 Æ05, Student’s two-tailed t-test). In
this experiment, the control group (which received ‘no luc’ phage) was analysed at both 1 and 3 days following phage delivery. The luc signal
measured in these control animals fell below the background cut-off of the assay (h,2 4h ;j, 72 h).
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from animals that were injected with 3JCLI4-targeted
phage, when compared with untargeted phage. The results
achieved statistical signiﬁcance at the day 3 time point.
Similar ﬁndings were obtained when luc activity was
measured by direct in vivo imaging of gene expression
using the Xenogen IVIS system (Fig. 5d).
In order to determine whether the increase in luc
expression might be secondary to changes in the physical
stability of phage particles that display the integrin-bind-
ing 3JCLI4 peptide on their surface, follow-up studies
were conducted. These experiments assessed the stability
of the 3JCLI4-targeted (luc) phage vs wild-type gpD (luc)
and wild-type lambdaD1180 grown via a lytic method. To
mimic in vivo conditions, phages were incubated in naı ¨ve
BALB/c mouse sera at 37 C (Fig. 6a). Phages were also
incubated in various concentrations of EDTA (Fig. 6b) and
SDS (Fig. 6c). There were no statistically signiﬁcant differ-
ences in stability of 3JCLI4-targeted (luc) phage vs wild-
type gpD (luc), except at the highest concentrations of SDS
tested (0Æ02% and 0Æ2%). However, these extreme condi-
tions resulted in almost complete loss of phage infectivity
(>99%), regardless of the coat protein composition of the
phage particles. Thus, it seems unlikely that the increase in
in vivo luc expression observed in mice receiving 3JCLI4
(luc) phage is due to an effect on phage stability.
Phage-mediated gene transfer is modestly affected by
depletion of phagocytic cells
To determine whether phage particles might be taken up
via phagocytosis, as suggested by March and coworkers
(Clark and March 2004; Jepson and March 2004; March
et al. 2004), luc expression was measured following
in vivo depletion of phagocytic cells. Brieﬂy, clodronate-
containing liposomes were administered to mice, in such
a way as to deplete phagocytic cells both locally and sys-
temically (van Rooijen and van Nieuwmegen 1984; van
Rooijen et al. 1989; van Rooijen and van Kesteren-Hend-
rikx 2002). Forty-eight hours thereafter, 1 · 10
11 PFU of
either wild-type gpD (luc) phage or targeted 3JCLI4 (luc)
phage, or 100 lg luc-encoding plasmid DNA (gWiz) was
injected ID. A moderate decrease in luc gene expression
was detected in animals that had been pretreated with
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Figure 6 Surface display of an integrin-binding peptide (3JCLI4) does
not alter the physical stability of lambda phage particles. The physical
stability of various lambda phage particles was assessed using a panel
of in vitro assays. For these experiments, the lambdaD1180 (luc)
phage genome, which contains an amber termination mutation in the
gpD coat protein gene, was packaged into phage particles either
using an in vitro complementation system to express wild-type gpD
(black bars) or gpD-3JCLI4 fusion protein (grey bars) on the phage
surface (Zanghi et al. 2005) or by lytic-phase growth of the phage in
Escherichia coli host cells containing an amber suppressor gene (‘lytic
phage’, denoted by dotted bars). The physical stability of the resulting
phage particles was assessed. Phages were incubated in naı ¨ve BALB/c
mouse sera (diluted 1:10 in SM) at 37 C for 30 min (a), or in increas-
ing concentrations of EDTA (b) and SDS (c), as described in the Mate-
rials and Methods section. Data shown represent mean phage titre
values ± SDs. There were no statistically signiﬁcant differences in the
stability of phage bearing the chimeric gpD fusion protein (3JCLI4;
grey bars), when compared with otherwise identical phage that dis-
played only wild-type gpD coat protein (gpD; black bars), except at
the highest concentrations of SDS (0Æ02% and 0Æ2%). However, these
SDS concentrations resulted in almost complete inactivation of phage
infectivity (>99%), regardless of the coat protein composition of the
phage particles.
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did not achieve statistical signiﬁcance (Fig. 7a). The
efﬁciency of clodronate-mediated cell depletion was
conﬁrmed by immunophenotyping of splenocytes using
an antibody speciﬁc for F4/80 (a cell surface marker
expressed on macrophages) (Fig. 7b).
Discussion
Bacteriophage lambda represents a promising gene trans-
fer/vaccine delivery system. March and colleagues recently
showed that unmodiﬁed lambda phage particles encoding
HbsAg under the control of a CMV promoter can elicit
strong humoural immune responses in mice and rabbits
after booster vaccinations (Clark and March 2004; March
et al. 2004).
In light of these ﬁndings, we wished to examine the
mechanism(s) by which unmodiﬁed lamdba phage parti-
cles might transduce mammalian cells in vivo, and to
explore ways in which this might be enhanced. We there-
fore developed an in vivo assay, which would allow us to
quantify phage-mediated gene transfer in live animals,
using the Xenogen IVIS system. We then used this system
to address basic questions concerning phage-mediated
gene transfer and immunization.
March and coworkers reported increased antibody
responses following multiple IM injections of their
HBsAg-encoding phage particles (Clark and March 2004;
March et al. 2004) and speculated that this might reﬂect
antibody-mediated opsonization of phage during subse-
quent immunizations, resulting in more efﬁcient
uptake by APCs (March et al. 2004). In keeping with this
prediction, we found that the presence of pre-existing
phage-speciﬁc antibodies (elicited by immunization with
wild-type phage) was associated with an increase in
phage-mediated reporter gene expression.
We also created modiﬁed phage particles that con-
tained speciﬁc modiﬁcations to the major coat protein,
gpD, intended to allow phage particles to more efﬁciently
bind and transduce host APCs (Zanghi et al. 2005). Phage
vectors that displayed a peptide known to bind to the
avb3 integrin receptor (Richards et al. 2003) were found
to be efﬁciently internalized into mammalian cells that
expressed this receptor, and to mediate an enhanced efﬁ-
ciency of gene transfer in avb3-positive cells, vs otherwise
identical host cells that did not express this receptor.
Interestingly, there was a 100-fold increase in the efﬁ-
ciency of phage internalization into avb3-positive cells vs
control cells (Fig. 5a), but only about a threefold increase
in the level of phage-mediated gene expression (Fig. 5b).
This suggests that only a small fraction of the internalized
phage particles were able to effectively deliver their gen-
etic payload.
Consistent with the results of these in vitro experi-
ments, in vivo studies suggest that targeting of phage to
integrin receptors can indeed increase the efﬁciency of
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Figure 7 In vivo luciferase (luc) expression in BALB/c mice injected
with wild-type or 3JCLI4-targeted phage is only modestly affected by
clodronate-mediated depletion of phagocytic cells. (a) Mice (four per
group) were injected with clodronate liposomes via a combined IP
and ID route, to deplete both local and systemic phagocytic cells
(black bars) or were left untreated (white bars). Forty-eight hours
later, 1 · 10
11 PFU of either gpD (luc) phage or 3JCLI4 (luc) phage, or
100 lg of gWIZ (luc) plasmid DNA was injected ID at the tail base
site, and luc expression was measured 24 h thereafter at the tail base
site of injection. A decrease in in vivo luc gene expression in animals
treated with clodronate liposomes prior to phage or DNA injection
was observed, although this decrease was not statistically signiﬁcant
(P >0 Æ05, Student’s two-tailed t-test). (b) After imaging, mice were
killed and splenocytes were stained for F4/80 (a cell surface marker
for macrophages). Mice that received clodronate liposomes had a
decrease in F4/80-positive splenocytes, as measured by ﬂow cytomet-
ric analysis. A representative staining proﬁle for one control animal
(left) and one clodronate-treated animal (right) is shown in the lower
part of panel b, and mean data from all animals are shown in graphi-
cal form in the upper part of panel B (bars denote SDs).
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the tail base route, although we cannot formally rule out
the possibility that the 3JCLI4–gpD coat protein modiﬁ-
cation may result in extended phage persistence at the
local site of injection (hence giving rise to increased
expression at the 72 h time point).
In order to try to address possible differences in the
physical stability of wild type vs modiﬁed phage capsids,
we performed a series of experimental analyses, using
EDTA, SDS and serum exposure. These experiments were
especially important, because our phage particles were
generated using a trans-complementation system, in which
the gpD coat protein is constitutively expressed from a
bacterial plasmid, in a gpD-deﬁcient lambda lysogen
(Sternberg and Hoess 1995; Eguchi et al. 2001; Zanghi
et al. 2005). It is possible that this complementation sys-
tem may generate phage particles that have an inherent
head instability created by this complementation system,
particularly if some phage particles contain less than nor-
mal levels of gpD. Reduced levels of major coat protein
are known to result in particle instability in certain
lambda recombinants (Wendt and Feiss 2004), and an
analogous coat protein in the dsDNA phage P4 is believed
to function by preventing DNA leakage from the phage
head (Dokland et al. 1993; Isaksen et al. 1993). We there-
fore performed a series of experiments to examine the
physical stability of our gpD-complemented phage parti-
cles. These experiments showed that the physical stability
of phage particles containing the wild-type gpD protein or
the 3JCLI4–gpD fusion protein was essentially indistin-
guishable. The particles were also found to be of essen-
tially equivalent stability to phage particles that contained
an identical lambda DNA genome, but which were gener-
ated using a completely different method that did not rely
upon coat protein complementation (these particles were
produced by lytic-phase growth of the lambdaD1180
phage in E. coli host cells that were able to suppress the
amber mutation in the endogenous phage gpD gene).
In order to address the mechanism of phage-mediated
gene transfer, and to test whether phagocytosis was
required for this process, mice were pretreated with clodr-
onate-containing liposomes. This resulted in extensive
depletion of phagocytic cells but did not signiﬁcantly
decrease phage-mediated gene transfer (although a non-
signiﬁcant trend towards reduced luc expression was
detected). The simplest explanation for these ﬁndings is
that phagocytosis is responsible for a portion, but not the
majority, of phage-mediated gene transfer. It is therefore
likely that other uptake mechanisms may contribute
to the uptake of phage particles and expression of
phage-encoded proteins. These include macropinocytosis,
a process that is induced by many microbial pathogens
(Swanson and Watts 1995; Amyere et al. 2002).
Cell types capable of performing macropinocytosis
include epithelial cells and keratinocytes (Zenni et al.
2000; Basner-Tschakarjan et al. 2004), which would not
be depleted by exposure to clodronate liposomes, as well
as CD8+ interdigitating DC, which are known to be
clodronate-resistant – unlike marginal DC and macroph-
ages (Leenen et al. 1998). Further studies will be needed
to determine whether macropinocytosis does indeed con-
tribute to phage-mediated gene transfer. This might
explain previous reports that a human ﬁbroblast cell line
(CCL-72 cells) can be transduced by wild-type lambda
phage particles under high (4 · 10
5) MOI conditions,
leading to transcription of phage-encoded genes within
the human host cells (Merril et al. 1971; Geier and Merril
1972). It is important to note, however, that the experi-
ment with clodronate liposomes was performed only
using nonmodiﬁed phage particles in naı ¨ve host animals.
Hence, the conclusion that phage particles are taken up
in large part by nonphagocytic cells may not apply to
integrin-targeted phage or to phage:antibody conjugates.
Previous studies from the March group have examined
immune responses to lambda phage-encoded gene prod-
ucts rather than phage-directed gene expression per se
(Clark and March 2004; Jepson and March 2004; March
et al. 2004,2006). These studies concluded that phage was
superior to a matched plasmid vector, from the stand-
point of inducing a humoural immune response to an
encoded antigen driven from a CMV promoter (Clark
and March 2004; Jepson and March 2004; March et al.
2004). In contrast, our experiments suggest that total lev-
els of in vivo reporter protein expression are very roughly
equivalent for naked DNA delivery vs lambda phage
delivery, at least when following ID delivery of unmodi-
ﬁed phage particles in naı ¨ve mice. This suggests that
phage vectors may be more efﬁcient in transducing key
cell types that are necessary for efﬁcient antigen presenta-
tion in vivo, when compared with naked plasmid DNA.
Whether this is due to direct transduction of professional
APC, such as dendritic cells [or speciﬁc, clodronate-resist-
ant subsets of DC (Leenen et al. 1998; Ciavarra et al.
2000)], or the result of transduction of other cell types
(and subsequent cross-presentation of phage-encoded
antigens), remains to be determined.
In summary, our results also show that speciﬁc surface
modiﬁcations of the phage particles (such as inclusion of
the integrin-targeting peptide) result in increased levels of
phage-mediated gene transfer. These results are compat-
ible with a model in which phage particles may induce
or enhance cellular macropinocytosis, possibly via the
engagement of speciﬁc cell surface receptors or signalling
pathways (Dharmawardhane et al. 2000). Moreover, these
ﬁndings are consistent with previous studies using gpD-
complemented lambda phage particles, which have shown
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increased through surface display of the HIV-1 Tat pro-
tein transduction domain (PTD) (Eguchi et al. 2001).
This PTD is known to engage a macropinocytosis-
dependent cell uptake pathway (Wadia et al. 2004). Par-
enthetically, this PTD also contains highly basic residues
that may alter the electrostatic properties of the phage
surface.
Overall, our work has increased the understanding of
lambda-phage-mediated gene transfer and suggests new
approaches that may lead to the design of second-genera-
tion phage vectors with improved gene transfer character-
istics.
Acknowledgements
We thank Sol Marie Rodriguez-Colon for technical assist-
ance, Casey Maguire and Drs Scott Blystone (SUNY Up-
state Medical University, Syracuse, NY, USA) and
Edith Lord (URMC) for providing reagents, Dr Stan
Hattman for sharing lab space, Drs Andrea Plu ¨ckthun
and Dr Patrick Forrer (University of Zurich) for provi-
ding gpD-encoding plasmids, and Dr Mahito Nakanishi
and DNAVEC Corp. for providing us with lambda phage
vectors [lambdaD1180 (luc) and lambdaD1180 (no luc)].
This work was supported by NIH grants: R21 AI058791
(to SD, CC); NIH F31 AI054330 (to KS); NIH P01
AI056356 (to CMPD); T32 AI007362 (to CNZ) and T32
GM07356 (to CNZ, CMPD).
References
Amyere, M., Mettlen, M., Van Der Smissen, P., Platek, A.,
Payrastre, B., Veithen, A. and Courtoy, P.J. (2002) Origin,
originality, functions, subversions and molecular signalling
of macropinocytosis. Int J Med Microbiol 291, 487–494.
Asada-Mikami, R., Heike, Y., Kanai, S., Azuma, M., Shirakawa,
K., Takaue, Y., Krasnykh, V., Curiel, D.T. et al. (2001)
Efﬁcient gene transduction by RGD-ﬁber modiﬁed recom-
binant adenovirus into dendritic cells. Jpn J Cancer Res 92,
321–327.
Barrow, P.A. and Soothill, J.S. (1997) Bacteriophage therapy
and prophylaxis: rediscovery and renewed assessment of
potential. Trends Microbiol 5, 268–271.
Basner-Tschakarjan, E., Mirmohammadsadegh, A., Baer, A.
and Hengge, U.R. (2004) Uptake and trafﬁcking of DNA
in keratinocytes: evidence for DNA-binding proteins. Gene
Ther 11, 765–774.
Chen, B.Y. and Lim, H.C. (1996) Bioreactor studies on tem-
perature induction of the Q-mutant of bacteriophage
lambda in Escherichia coli. J Biotechnol 51, 1–20.
Ciavarra, R.P., Greene, A.R., Horeth, D.R., Buhrer, K., van
Rooijen, N. and Tedeschi, B. (2000) Antigen processing of
vesicular stomatitis virus in situ. Interdigitating dendritic
cells present viral antigens independent of marginal dend-
ritic cells but fail to prime CD4(+) and CD8(+) T cells.
Immunology 101, 512–520.
Clark, J.R. and March, J.B. (2004) Bacteriophage-mediated
nucleic acid immunisation. FEMS Immunol Med Microbiol
40, 21–26.
Cowan, K.M. (1962) Studies on the coliphage neutralizing
activity of normal human serum. J Immunol 88, 476–481.
Dharmawardhane, S., Schurmann, A., Sells, M.A., Chernoff, J.,
Schmid, S.L. and Bokoch, G.M. (2000) Regulation of mac-
ropinocytosis by p21-activated kinase-1. Mol Biol Cell 11,
3341–3352.
Dokland, T., Isaksen, M.L., Fuller, S.D. and Lindqvist, B.H.
(1993) Capsid localization of the bacteriophage P4 Psu
protein. Virology 194, 682–687.
Dunn, I.S. (1996) Mammalian cell binding and transfection
mediated by surface-modiﬁed bacteriophage lambda.
Biochimie 78, 856–861.
Eguchi, A., Akuta, T., Okuyama, H., Senda, T., Yokoi, H., Ino-
kuchi, H., Fujita, S., Hayakawa, T. et al. (2001) Protein
transduction domain of HIV-1 Tat protein promotes efﬁ-
cient delivery of DNA into mammalian cells. J Biol Chem
276, 26204–26210.
Fan, S., Maguire, C.A., Ramirez, S.H., Bradel-Tretheway, B.,
Sapinoro, R., Sui, Z., Chakraborty-Sett, S. and Dewhurst,
S. (2005) Valproic acid enhances gene expression from
viral gene transfer vectors. J Virol Methods 125, 23–33.
Gavrilovskaya, I.N., Shepley, M., Shaw, R., Ginsberg, M.H. and
Mackow, E.R. (1998) Beta3 integrins mediate the cellular
entry of hantaviruses that cause respiratory failure. Proc
Natl Acad Sci USA 95, 7074–7079.
Geier, M.R. and Merril, C.R. (1972) Lambda phage transcrip-
tion in human ﬁbroblasts. Virology 47, 638–643.
Harui, A., Roth, M.D., Sanghvi, M., Vira, D., Mizuguchi, H.
and Basak, S.K. (2006a) Centrifugation enhances integrin-
mediated transduction of dendritic cells by conventional
and RGD-modiﬁed adenoviral vectors. J Immunol Methods
312, 94–104.
Harui, A., Roth, M.D., Vira, D., Sanghvi, M., Mizuguchi, H.
and Basak, S.K. (2006b) Adenoviral-encoded antigens are
presented efﬁciently by a subset of dendritic cells expres-
sing high levels of av/b3 integrins. J Leukoc Biol 79, 1271–
1278.
Huang, S., Endo, R.I. and Nemerow, G.R. (1995) Upregulation
of integrins alphavbeta3 and alphavbeta5 on human
monocytes and T lymphocytes facilitates adenovirus-medi-
ated gene delivery. J Virol 69, 2257–2263.
Isaksen, M.L., Dokland, T. and Lindqvist, B.H. (1993) Charac-
terization of the capsid associating activity of bacterio-
phage P4’s Psu protein. Virology 194, 674–681.
Jepson, C.D. and March, J.B. (2004) Bacteriophage lambda is a
highly stable DNA vaccine delivery vehicle. Vaccine 22,
2413–2419.
H.A. Lankes et al. In vivo gene transfer by phage k
ª 2006 The Authors
Journal compilation ª 2006 The Society for Applied Microbiology, Journal of Applied Microbiology 102 (2007) 1337–1349 1347Larocca, D., Witte, A., Johnson, W., Pierce, G.F. and Baird, A.
(1998) Targeting bacteriophage to mammalian cell surface
receptors for gene delivery. Hum Gene Ther 9, 2393–2399.
Larocca, D., Kassner, P.D., Witte, A., Ladner, R.C., Pierce, G.F.
and Baird, A. (1999) Gene transfer to mammalian cells
using genetically targeted ﬁlamentous bacteriophage. FAS-
EB J 13, 727–734.
Leenen, P.J., Radosevic, K., Voerman, J.S., Salomon, B., van
Rooijen, N., Klatzmann, D. and van Ewijk, W. (1998) Het-
erogeneity of mouse spleen dendritic cells: in vivo phago-
cytic activity, expression of macrophage markers, and
subpopulation turnover. J Immunol 160, 2166–2173.
Maguire, C.A., Sapinoro, R., Girgis, N., Rodriguez-Colon,
S.M., Ramirez, S.H., Williams, J. and Dewhurst, S. (2006)
Recombinant adenovirus type 5 vectors that target DC-
SIGN, ChemR23 and alpha(v)beta3 integrin efﬁciently
transduce human dendritic cells and enhance presentation
of vectored antigens. Vaccine 24, 671–682.
March, J.B., Clark, J.R. and Jepson, C.D. (2004) Genetic
immunisation against hepatitis B using whole bacterio-
phage lambda particles. Vaccine 22, 1666–1671.
March, J.B., Jepson, C.D., Clark, J.R., Totsika, M. and Cal-
cutt, M.J. (2006) Phage library screening for the rapid
identiﬁcation and in vivo testing of candidate genes for
a DNA vaccine against Mycoplasma mycoides subsp.
mycoides small colony biotype. Infect Immun 74, 167–
174.
Mathias, P., Wickham, T., Moore, M. and Nemerow, G.
(1994) Multiple adenovirus serotypes use alpha v integrins
for infection. J Virol 68, 6811–6814.
Maurer, P., Jennings, G.T., Willers, J., Rohner, F., Lindman,
Y., Roubicek, K., Renner, W.A., Muller, P. et al. (2005) A
therapeutic vaccine for nicotine dependence: preclinical
efﬁcacy, and phase I safety and immunogenicity. Eur J
Immunol 35, 2031–2040.
Merril, C.R., Geier, M.R. and Petricciani, J.C. (1971) Bacterial
virus gene expression in human cells. Nature 233, 398–
400.
O’Doherty, U., Swiggard, W.J. and Malim, M.H. (2000)
Human immunodeﬁciency virus type 1 spinoculation
enhances infection through virus binding. J Virol 74,
10074–10080.
Okada, N., Tsukada, Y., Nakagawa, S., Mizuguchi, H., Mori,
K., Saito, T., Fujita, T., Yamamoto, A. et al. (2001) Efﬁ-
cient gene delivery into dendritic cells by ﬁber-mutant
adenovirus vectors. Biochem Biophys Res Commun 282,
173–179.
Richards, J., Miller, M., Abend, J., Koide, A., Koide, S. and
Dewhurst, S. (2003) Engineered ﬁbronectin type III
domain with a RGDWXE sequence binds with enhanced
afﬁnity and speciﬁcity to human alphavbeta3 integrin.
J Mol Biol 326, 1475–1488.
van Rooijen, N. and van Kesteren-Hendrikx, E. (2002) Clodro-
nate liposomes: perspectives in research and therapeutics.
J Liposome Res 12, 81–94.
van Rooijen, N. and van Nieuwmegen, R. (1984) Elimination
of phagocytic cells in the spleen after intravenous injection
of liposome-encapsulated dichloromethylene diphospho-
nate. An enzyme-histochemical study. Cell Tissue Res 238,
355–358.
van Rooijen, N., Kors, N. and Kraal, G. (1989) Macrophage
subset repopulation in the spleen: differential kinetics
after liposome-mediated elimination. J Leukoc Biol 45,
97–104.
Rubartelli, A., Poggi, A. and Zocchi, M.R. (1997) The selective
engulfment of apoptotic bodies by dendritic cells is
mediated by the alpha(v)beta3 integrin and requires
intracellular and extracellular calcium. Eur J Immunol 27,
1893–1900.
Scanlan, P.M., Tiwari, V., Bommireddy, S. and Shukla, D.
(2005) Spinoculation of heparan sulfate deﬁcient cells
enhances HSV-1 entry, but does not abolish the need for
essential glycoproteins in viral fusion. J Virol Methods 128,
104–112.
Schluederberg, S.A., Marshall, B., Tachibana, C. and Levy,
S.B. (1980) Recovery frequency of phages lambda and
M13 from human and animal faeces. Nature 283,
792–794.
Song, J.W., Song, K.J., Baek, L.J., Frost, B., Poncz, M. and
Park, K. (2005) In vivo characterization of the integrin
beta3 as a receptor for Hantaan virus cellular entry. Exp
Mol Med 37, 121–127.
Sternberg, N. and Hoess, R.H. (1995) Display of peptides and
proteins on the surface of bacteriophage lambda. Proc Natl
Acad Sci USA 92, 1609–1613.
Stone, R. (2002) Bacteriophage therapy. Stalin’s forgotten cure.
Science 298, 728–731.
Swanson, J.A. and Watts, C. (1995) Macropinocytosis. Trends
Cell Biol 5, 424–428.
Wadia, J.S., Stan, R.V. and Dowdy, S.F. (2004) Transducible
TAT-HA fusogenic peptide enhances escape of TAT-fusion
proteins after lipid raft macropinocytosis. Nat Med 10,
310–315.
Wendt, J.L. and Feiss, M. (2004) A fragile lattice: replacing
bacteriophage lambda’s head stability gene D with the shp
gene of phage 21 generates the Mg2+-dependent virus,
lambda shp. Virology 326, 41–46.
Wickham, T.J., Mathias, P., Cheresh, D.A. and Nemerow, G.R.
(1993) Integrins alphavbeta3 and alphavbeta5 promote
adenovirus internalization but not virus attachment. Cell
73, 309–319.
Zanghi, C.N., Lankes, H.A., Bradel-Tretheway, B., Wegman, J.
and Dewhurst, S. (2005) A simple method for displaying
recalcitrant proteins on the surface of bacteriophage
lambda. Nucleic Acids Res 33, e160.
Zenni, M.K., Giardina, P.C., Harvey, H.A., Shao, J., Ketterer,
M.R., Lubaroff, D.M., Williams, R.D. and Apicella, M.A.
(2000) Macropinocytosis as a mechanism of entry into pri-
mary human urethral epithelial cells by Neisseria gonor-
rhoeae. Infect Immun 68, 1696–1699.
In vivo gene transfer by phage k H.A. Lankes et al.
1348 Journal compilation ª 2006 The Society for Applied Microbiology, Journal of Applied Microbiology 102 (2007) 1337–1349
ª 2006 The AuthorsSupplementary Material
The following supplementary material is available for this
article online:
Figure S1 In vivo luciferase (luc) expression in BALB/c
mice is localized to the tissue site of injection. Mice were
injected ID at the tail base with 1 · 10
11 PFU of gpD
(luc) phage (a) or 1 · 10
11 PFU of gpD (no luc) phage
(b). Twenty-four hours later, luc expression was imaged
at the tail base site of injection. The results are shown for
a representative set of three animals.
This material is available as part of the online article
from http://www.blackwell-synergy.com
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